Healthcare provider profile · identity verified

Tyler Witzel, DO

Family Practice · LAS VEGAS, NV · NPI 1972908150

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	212	85
Lisinopril	Lisinopril	142	53
Amlodipine Besylate	Amlodipine Besylate	137	65
Fluticasone Propionate	Fluticasone Propionate	130	65
Levothyroxine Sodium	Levothyroxine Sodium	114	49
Azithromycin	Azithromycin	113	103
Metformin Hcl	Metformin Hcl	103	38
Losartan Potassium	Losartan Potassium	102	47
Rosuvastatin Calcium	Rosuvastatin Calcium	91	39
Hydrochlorothiazide	Hydrochlorothiazide	86	35
Tamsulosin Hcl	Tamsulosin Hcl	83	32
Omeprazole	Omeprazole	82	32
Pantoprazole Sodium	Pantoprazole Sodium	75	30
Gabapentin	Gabapentin	65	39
Albuterol Sulfate Hfa	Albuterol Sulfate	63	33
Metoprolol Succinate	Metoprolol Succinate	57	26
Naproxen	Naproxen	57	41
Eliquis	Apixaban	51	21
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	51	26
Potassium Chloride	Potassium Chloride	45	21
Prednisone	Prednisone	45	40
Nitrofurantoin Mono-Macro	Nitrofurantoin Monohyd/M-Cryst	44	42
Sertraline Hcl	Sertraline Hcl	42	17
Furosemide	Furosemide	39	21
Tizanidine Hcl	Tizanidine Hcl	39	25
Tramadol Hcl	Tramadol Hcl	37	21
Alendronate Sodium	Alendronate Sodium	36	15
Alprazolam	Alprazolam	35	15
Metoprolol Tartrate	Metoprolol Tartrate	35	15
Hydroxyzine Hcl	Hydroxyzine Hcl	33	20
Ondansetron Odt	Ondansetron	33	25
Simvastatin	Simvastatin	33	19
Carvedilol	Carvedilol	30	13
Clopidogrel	Clopidogrel Bisulfate	30	11
Metformin Hcl Er	Metformin Hcl	29	13
Montelukast Sodium	Montelukast Sodium	29	12
Triamcinolone Acetonide	Triamcinolone Acetonide	28	15
Baclofen	Baclofen	26	18
Diclofenac Sodium	Diclofenac Sodium	26	12
Famotidine	Famotidine	26	14
Zolpidem Tartrate	Zolpidem Tartrate	26	suppressed
Glipizide	Glipizide	24	suppressed
Jardiance	Empagliflozin	24	14
Amoxicillin-Clavulanate Potass	Amoxicillin/Potassium Clav	23	22
Trelegy Ellipta	Fluticasone/Umeclidin/Vilanter	22	suppressed
Finasteride	Finasteride	21	suppressed
Buspirone Hcl	Buspirone Hcl	20	suppressed
Ciprofloxacin Hcl	Ciprofloxacin Hcl	19	15
Symbicort	Budesonide/Formoterol Fumarate	19	suppressed
Meclizine Hcl	Meclizine Hcl	18	suppressed
Meloxicam	Meloxicam	18	suppressed
Escitalopram Oxalate	Escitalopram Oxalate	17	suppressed
Glipizide Er	Glipizide	16	suppressed
Hydralazine Hcl	Hydralazine Hcl	16	suppressed
Lovastatin	Lovastatin	16	suppressed
Atenolol	Atenolol	15	suppressed
Dropsafe Prep Pads	Alcohol Antiseptic Pads	15	suppressed
Ezetimibe	Ezetimibe	15	suppressed
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	15	suppressed
Oxybutynin Chloride	Oxybutynin Chloride	15	suppressed
Pravastatin Sodium	Pravastatin Sodium	15	suppressed
Sucralfate	Sucralfate	15	suppressed
Trazodone Hcl	Trazodone Hcl	14	suppressed
Citalopram Hbr	Citalopram Hydrobromide	13	suppressed
Januvia	Sitagliptin Phosphate	13	suppressed
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	13	suppressed
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	13	suppressed
Mirtazapine	Mirtazapine	13	suppressed
Sildenafil Citrate	Sildenafil Citrate	13	suppressed
Sulfamethoxazole-Trimethoprim	Sulfamethoxazole/Trimethoprim	13	12
Breztri Aerosphere	Budesonide/Glycopyr/Formoterol	12	suppressed
Ciclopirox	Ciclopirox Olamine	12	suppressed
Donepezil Hcl	Donepezil Hcl	12	suppressed
Duloxetine Hcl	Duloxetine Hcl	12	suppressed
Methylprednisolone	Methylprednisolone	12	suppressed
Mounjaro	Tirzepatide	12	suppressed
Chlorthalidone	Chlorthalidone	11	suppressed
Doxycycline Hyclate	Doxycycline Hyclate	11	suppressed
Levocetirizine Dihydrochloride	Levocetirizine Dihydrochloride	11	suppressed
Methocarbamol	Methocarbamol	11	suppressed
Oxycodone Hcl	Oxycodone Hcl	11	suppressed
Pregabalin	Pregabalin	11	suppressed
Ropinirole Hcl	Ropinirole Hcl	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error